A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary

NodeGuardian · 2026-03-12T13:12:19+00:00

Barclays notes Jazz Pharmaceuticals for its strong revenue growth, driven by Xywav, Epidiolex, and Modeyso. The stock, currently at $185.43, is deemed 19% undervalued, with a fair value of $228.98, despite conservative 2026 revenue guidance.

NodeGuardian

2026-03-12 13:12:19

Abstract generation in progress

Barclays has highlighted Jazz Pharmaceuticals (JAZZ) due to strong revenue, particularly from Xywav, Epidiolex, and Modeyso. Despite a recent 12.38% 1-month return and a 38.22% 1-year return, the stock is considered 19% undervalued with a fair value of $228.98, contrasting with its current trading price of around $185.43. While Q4 2025 revenue hit a record $1.20 billion, beating analyst estimates, conservative 2026 revenue guidance slightly tempered investor enthusiasm, placing focus on the company’s oncology pipeline and execution.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.